Active	Status	Sponsor type	Region	Phase	Filter
8 Active 7 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
masupirdine (SUVN-502) / Suven Life Sci
2021-003405-22: Research study to assess the potential of masupirdine in patients with agitation symptoms associated with memory loss	Ongoing	3	375	Europe, RoW	Masupirdine, SUVN-502, Tablet	Suven Life Sciences Ltd., Suven Life Sciences Ltd	Agitation with Dementia of the Alzheimer's Type, Agitation symptoms associated with memory loss, Diseases [C] - Nervous System Diseases [C10]
NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type	Recruiting	3	375	Europe, US, RoW	Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo	Suven Life Sciences Limited, Suven Life Sciences Ltd	Agitation, Alzheimer's Type Dementia	12/25	12/25
SUVN-502, NCT03564964: Expanded Access to Provide for the Treatment of Subjects With Alzheimer's Disease	No Longer Available	N/A		NA	SUVN-502	Suven Life Sciences Limited	Alzheimer Disease, Dementia, Cognition Disorders
samelisant (SUVN-G3031) / Suven Life Sci
SUVN-G3031, NCT04072380: A Study to Evaluate Safety, and Efficacy of (Samelisant) in Patients With Narcolepsy With and Without Cataplexy	Completed	2	190	Canada, US	SUVN-G3031, Samelisant, Placebo	Suven Life Sciences Limited	Narcolepsy	06/23	06/23
NCT05530447: Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy	No Longer Available	N/A		NA	Samelisant, SUVN-G3031	Suven Life Sciences Limited	Narcolepsy
ropanicant (SUVN-911) / Suven Life Sci
NCT06126497: Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients	Completed	2	41	US	Ropanicant, SUVN-911	Suven Life Sciences Limited	Major Depressive Disorder	07/24	07/24
NCT06836063: Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients	Not yet recruiting	2	195	NA	Ropanicant, SUVN-911, Placebo	Suven Life Sciences Limited	Major Depressive Disorder (MDD)	02/26	02/26
SUVN-I6107 / Suven Life Sci
NCT06705088: Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SUVN-I6107 In Healthy Participants	Recruiting	1	64	US	SUVN-I6107, Placebo	Suven Life Sciences Limited	Healthy	10/25	10/25
SUVN-6206012 / Suven Life Sci
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
masupirdine (SUVN-502) / Suven Life Sci
2021-003405-22: Research study to assess the potential of masupirdine in patients with agitation symptoms associated with memory loss	Ongoing	3	375	Europe, RoW	Masupirdine, SUVN-502, Tablet	Suven Life Sciences Ltd., Suven Life Sciences Ltd	Agitation with Dementia of the Alzheimer's Type, Agitation symptoms associated with memory loss, Diseases [C] - Nervous System Diseases [C10]
NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type	Recruiting	3	375	Europe, US, RoW	Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo	Suven Life Sciences Limited, Suven Life Sciences Ltd	Agitation, Alzheimer's Type Dementia	12/25	12/25
SUVN-502, NCT03564964: Expanded Access to Provide for the Treatment of Subjects With Alzheimer's Disease	No Longer Available	N/A		NA	SUVN-502	Suven Life Sciences Limited	Alzheimer Disease, Dementia, Cognition Disorders
samelisant (SUVN-G3031) / Suven Life Sci
SUVN-G3031, NCT04072380: A Study to Evaluate Safety, and Efficacy of (Samelisant) in Patients With Narcolepsy With and Without Cataplexy	Completed	2	190	Canada, US	SUVN-G3031, Samelisant, Placebo	Suven Life Sciences Limited	Narcolepsy	06/23	06/23
NCT05530447: Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy	No Longer Available	N/A		NA	Samelisant, SUVN-G3031	Suven Life Sciences Limited	Narcolepsy
ropanicant (SUVN-911) / Suven Life Sci
NCT06126497: Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients	Completed	2	41	US	Ropanicant, SUVN-911	Suven Life Sciences Limited	Major Depressive Disorder	07/24	07/24
NCT06836063: Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients	Not yet recruiting	2	195	NA	Ropanicant, SUVN-911, Placebo	Suven Life Sciences Limited	Major Depressive Disorder (MDD)	02/26	02/26
SUVN-I6107 / Suven Life Sci
NCT06705088: Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SUVN-I6107 In Healthy Participants	Recruiting	1	64	US	SUVN-I6107, Placebo	Suven Life Sciences Limited	Healthy	10/25	10/25
SUVN-6206012 / Suven Life Sci
No trials found